Vascular adhesion protein-1: Role in human pathology and application as a biomarker

References

• Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 1992;257:1407–9
   PubMed Web of Science ®Google Scholar
• Noonan T, Lukas S, Peet GW, et al. The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function. Am J Clin Exp Immunol 2013;2:172–85
   PubMedGoogle Scholar
• Kaitaniemi S, Grön K, Elovaara H, et al. Functional modulation of vascular adhesion protein-1 by a novel splice variant. PLoS One 2013;8:e54151
   PubMed Web of Science ®Google Scholar
• Amine oxidase, copper-containing, 3; AOC3. *603735. Available at http://www.omim.org/entry/603735
   Google Scholar
• Bligt-Lindén E, Arunachalam R, Parkash V, Salminen TA. Structural comparison of the active site channels in rodent and primate vascular adhesion protein-1. J Neural Transm 2013;120:947–50
   PubMed Web of Science ®Google Scholar
• Airenne TT, Nymalm Y, Kidron H, et al. Crystal structure of the human vascular adhesion protein-1: unique structural features with functional implications. Protein Sci 2005;14:1964–74
   PubMed Web of Science ®Google Scholar
• Jakobsson E, Nilsson J, Ogg D, Kleywegt GJ. Structure of human semicarbazide-sensitive amine oxidase/vascular adhesion protein-1. Acta Crystallogr D Biol Crystallogr 2005;61:1550–62
   PubMed Web of Science ®Google Scholar
• Kurkijärvi R, Yegutkin GG, Gunson BK, et al. Circulating soluble vascular adhesion protein 1 accounts for the increased serum monoamine oxidase activity in chronic liver disease. Gastroenterology 2000;119:1096–103
   PubMed Web of Science ®Google Scholar
• Wang YC, Li HY, Wei JN, et al. Serum vascular adhesion protein-1 level is higher in smokers than non-smokers. Ann Hum Biol 2013;40:413–8
   PubMed Web of Science ®Google Scholar
• Aalto K, Maksimow M, Juonala M, et al. Soluble vascular adhesion protein-1 correlates with cardiovascular risk factors and early atherosclerotic manifestations. Arterioscler Thromb Vasc Biol 2012;32:523–32
   PubMed Web of Science ®Google Scholar
• Boomsma F, Bhaggoe UM, van der Houwen AM, van den Meiracker AH. Plasma semicarbazide-sensitive amine oxidase in human (patho)physiology. Biochim Biophys Acta 2003;1647:48–54
   PubMed Web of Science ®Google Scholar
• McEwen CM Jr, Castell DO. Abnormalities of serum monoamine oxidase in chronic liver disease. J Lab Clin Med 1967;70:36–47
   PubMed Web of Science ®Google Scholar
• Tufvesson G. Determination of monoamine oxidase activity in human blood serum with 14C-benzylamine and 14C-tyramine as substrates. Scand J Clin Lab Invest 1969;23:71–7
   PubMed Web of Science ®Google Scholar
• van Dijk J, Boomsma F, Alberts G, et al. Determination of semicarbazide-sensitive amine oxidase activity in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr B Biomed Appl 1995;663:43–50
   PubMed Web of Science ®Google Scholar
• Holt A, Palcic MM. A peroxidase-coupled continuous absorbance platereader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes. Nat Protoc 2006;1:2498–505
   PubMed Web of Science ®Google Scholar
• Lin MS, Li HY, Wei JN, et al. Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clin Biochem 2008;41:1362–7
   PubMed Web of Science ®Google Scholar
• Kurkijärvi R, Adams DH, Leino R, et al. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol 1998;161:1549–57
   PubMed Web of Science ®Google Scholar
• Dugué B, Leppänen E, Gräsbeck R. Preanalytical factors (biological variation) and the measurement of serum soluble intercellular adhesion molecule-1 in humans: influence of the time of day, food intake, and physical and psychological stress. Clin Chem 1999;45:1543–7
   PubMed Web of Science ®Google Scholar
• Hartweg J, Gunter M, Perera R, et al. Stability of soluble adhesion molecules, selectins, and C-reactive protein at various temperatures: implications for epidemiological and large-scale clinical studies. Clin Chem 2007;53:1858–60
   PubMed Web of Science ®Google Scholar
• Salmi M, Kalimo K, Jalkanen S. Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 1993;178:2255–60
   PubMed Web of Science ®Google Scholar
• Weston CJ, Shepherd EL, Adams DH. Cellular localization and trafficking of vascular adhesion protein-1 as revealed by an N-terminal GFP fusion protein. J Neural Transm 2013;120:951–61
   PubMed Web of Science ®Google Scholar
• Solé M, Unzeta M. Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases. Biol Cell 2011;103:543–57
   PubMed Web of Science ®Google Scholar
• Salmi M, Jalkanen S. Developmental regulation of the adhesive and enzymatic activity of vascular adhesion protein-1 (VAP-1) in humans. Blood 2006;108:1555–61
   PubMed Web of Science ®Google Scholar
• Smith DJ, Vainio PJ. Targeting vascular adhesion protein-1 to treat autoimmune and inflammatory diseases. Ann NY Acad Sci 2007;1110:382–8
   PubMed Web of Science ®Google Scholar
• Jaakkola K, Kaunismäki K, Tohka S, et al. Human vascular adhesion protein-1 in smooth muscle cells. Am J Pathol 1999;155:1953–65
   PubMed Web of Science ®Google Scholar
• Koskinen K, Vainio PJ, Smith DJ, et al. Granulocyte transmigration through endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 2004;103:3388–95
   PubMed Web of Science ®Google Scholar
• Salmi M, Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol 2005;5:760–71
   PubMed Web of Science ®Google Scholar
• Mercier N, Moldes M, El Hadri K, Feve B. Semicarbazide-sensitive amine oxidase activation promotes adipose conversion of 3T3-L1 cells. Biochem J 2001;358:335–42
   PubMed Web of Science ®Google Scholar
• Zorzano A, Abella A, Marti L, et al. Semicarbazide-sensitive amine oxidase activity exerts insulin-like effects on glucose metabolism and insulin-signaling pathways in adipose cells. Biochim Biophys Acta 2003;1647:3–9
   PubMed Web of Science ®Google Scholar
• Gokturk C, Nilsson J, Nordquist J, et al. Overexpression of semicarbazide-sensitive amine oxidase in smooth muscle cells leads to an abnormal structure of the aortic elastic laminas. Am J Pathol 2003;163:1921–8
   PubMed Web of Science ®Google Scholar
• Salmi M, Tohka S, Berg EL, et al. Vascular adhesion protein 1 (VAP-1) mediates lymphocyte subtype-specific, selectin-independent recognition of vascular endothelium in human lymph nodes. J Exp Med 1997;186:589–600
   PubMed Web of Science ®Google Scholar
• Tohka S, Laukkanen ML, Jalkanen S, Salmi M. Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates their recruitment in vivo. FASEB J 2001;15:373–82
   PubMed Web of Science ®Google Scholar
• Stolen CM, Marttila-Ichihara F, Koskinen K, et al. Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity 2005;22:105–15
   PubMed Web of Science ®Google Scholar
• Jaakkola K, Nikula T, Holopainen R, et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am J Pathol 2000;157:463–71
   PubMed Web of Science ®Google Scholar
• Salmi M, Jalkanen S. Human vascular adhesion protein-1 (VAP-1) is a unique sialoglycoprotein that mediates carbohydrate-dependent binding of lymphocytes to endothelial cells. J Exp Med 1996;183:569–79
   PubMed Web of Science ®Google Scholar
• Salmi M, Yegutkin G, Lehvonen R, et al. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 2001;14:265–76
   PubMed Web of Science ®Google Scholar
• Smith DJ, Salmi M, Bono P, et al. Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med 1998;188:17–27
   PubMed Web of Science ®Google Scholar
• Yu PH, Davis BA, Deng Y. 2-Bromoethylamine as a potent selective suicide inhibitor for semicarbazide-sensitive amine oxidase. Biochem Pharmacol 2001;61:741–8
   PubMed Web of Science ®Google Scholar
• Salter-Cid LM, Wang E, O'Rourke AM, et al. Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase. J Pharmacol Exp Ther 2005;315:553–62
   PubMed Web of Science ®Google Scholar
• Inoue T, Morita M, Tojo T, et al. Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment. Bioorg Med Chem 2013;21:3873–81
   PubMed Web of Science ®Google Scholar
• Esteban G, Bolea I, Sun P, et al. A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE. J Neural Transm 2013;120:911–18
   PubMed Web of Science ®Google Scholar
• Xu HL, Salter-Cid L, Linnik MD, et al. Vascular adhesion protein-1 plays an important role in postis chemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia. J Pharmacol Exp Ther 2006;317:19–29
   PubMed Web of Science ®Google Scholar
• Wang EY, Gao H, Salter-Cid L, et al. Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity. J Med Chem 2006;49:2166–73
   PubMed Web of Science ®Google Scholar
• O'Rourke AM, Wang EY, Miller A, et al. Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity. J Pharmacol Exp Ther 2008;324:867–75
   PubMed Web of Science ®Google Scholar
• Inoue T, Morita M, Tojo T, et al. Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema: part 2. Bioorg Med Chem 2013;21:2478–94
   PubMed Web of Science ®Google Scholar
• Inoue T, Morita M, Tojo T, et al. Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema. Bioorg Med Chem 2013;21:1219–33
   PubMed Web of Science ®Google Scholar
• Foot JS, Yow TT, Schilter H, et al. PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo. J Pharmacol Exp Ther 2013;347:365–74
   PubMed Web of Science ®Google Scholar
• Enzsöly A, Dunkel P, Récsán Z, et al. Preliminary studies of the effects of vascular adhesion protein-1 inhibitors on experimental corneal neovascularization. J Neural Transm 2011;118:1065–9
   PubMed Web of Science ®Google Scholar
• Marttila-Ichihara F, Auvinen K, Elima K, et al. Vascular adhesion protein-1 enhances tumor growth by supporting recruitment of Gr-1+CD11b + myeloid cells into tumors. Cancer Res 2009;69:7875–83
   PubMed Web of Science ®Google Scholar
• Marttila-Ichihara F, Castermans K, Auvinen K, et al. Small-molecule inhibitors of vascular adhesion protein-1 reduce the accumulation of myeloid cells into tumors and attenuate tumor growth in mice. J Immunol 2010;184:3164–73
   PubMed Web of Science ®Google Scholar
• Kirton CM, Laukkanen ML, Nieminen A, et al. Function-blocking antibodies to human vascular adhesion protein-1: a potential anti-inflammatory therapy. Eur J Immunol 2005;35:3119–30
   PubMed Web of Science ®Google Scholar
• Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, et al. Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis. Basic Clin Pharmacol Toxicol 2005;96:429–35
   PubMed Web of Science ®Google Scholar
• Bligt-Lindén E, Pihlavisto M, Szatmári I, et al. Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): old target-new inhibition mode. J Med Chem 2013;56:9837–48
   PubMed Web of Science ®Google Scholar
• Li HY, Lin MS, Wei JN, et al. Change of serum vascular adhesion protein-1 after glucose loading correlates to carotid intima-medial thickness in non-diabetic subjects. Clin Chim Acta 2009;403:97–101
   PubMed Web of Science ®Google Scholar
• Boomsma F, de Kam PJ, Tjeerdsma G, et al. Plasma semicarbazide-sensitive amine oxidase (SSAO) is an independent prognostic marker for mortality in chronic heart failure. Eur Heart J 2000;21:1859–63
   PubMed Web of Science ®Google Scholar
• Aalto K, Havulinna AS, Jalkanen S, et al. Soluble vascular adhesion protein-1 predicts incident major adverse cardiovascular events and improves reclassification in a Finnish prospective cohort study. Circ Cardiovasc Genet 2014;7:529–35
   PubMed Web of Science ®Google Scholar
• Bour S, Caspar-Bauguil S, Iffiú-Soltész Z, et al. Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 deficiency reduces leukocyte infiltration into adipose tissue and favors fat deposition. Am J Pathol 2009;174:1075–83
   PubMed Web of Science ®Google Scholar
• Raimondi L, Pirisino R, Banchelli G, et al. Cultured preadipocytes produce a semicarbazide-sensitive amine oxidase (SSAO) activity. J Neural Transm Suppl 1990;32:331–6
   PubMedGoogle Scholar
• Moldes M, Fève B, Pairault J. Molecular cloning of a major mRNA species in murine 3T3 adipocyte lineage differentiation-dependent expression, regulation, and identification as semicarbazide-sensitive amine oxidase. J Biol Chem 1999;274:9515–23
   PubMed Web of Science ®Google Scholar
• Bour S, Daviaud D, Gres S, et al. Adipogenesis-related increase of semicarbazide-sensitive amine oxidase and monoamine oxidase in human adipocytes. Biochimie 2007;89:916–25
   PubMed Web of Science ®Google Scholar
• Weiss HG, Klocker J, Labeck B, et al. Plasma amine oxidase: a postulated cardiovascular risk factor in nondiabetic obese patients. Metabolism 2003;52:688–92
   PubMed Web of Science ®Google Scholar
• Iffiú-Soltész Z, Mercader J, Daviaud D, et al. Increased primary amine oxidase expression and activity in white adipose tissue of obese and diabetic db−/− mice. J Neural Transm 2011;118:1071–7
   PubMed Web of Science ®Google Scholar
• Carpéné C, Abello V, Iffiú-Soltész Z, et al. Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res 2008;57:426–34
   PubMed Web of Science ®Google Scholar
• Carpéné C, Iffiú-Soltesz Z, Bour S, et al. Reduction of fat deposition by combined inhibition of monoamine oxidases and semicarbazide-sensitive amine oxidases in obese Zucker rats. Pharmacol Res 2007;56:522–30
   PubMed Web of Science ®Google Scholar
• Enrique-Tarancon G, Mart L, Lizcano JM, et al. Role of semicarbazide-sensitive amine oxidase on glucose transport and GLUT4 recruitment to the cell surface in adipose cell. J Biol Chem 1998;273:8025–32
   PubMed Web of Science ®Google Scholar
• Boomsma F, van den Meiracker AH, Winke S, et al. Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis. Diabetologia 1999;42:233–7
   PubMed Web of Science ®Google Scholar
• Li HY, Jiang YD, Chang TJ, et al. Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes. Diabetes 2011;60:993–9
   PubMed Web of Science ®Google Scholar
• Li HY, Wei JN, Lin MS, et al. Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia. Clin Chim Acta 2009;404:149–53
   PubMed Web of Science ®Google Scholar
• Somfai GM, Knippel B, Ruzicska E, et al. Soluble semicarbazide-sensitive amine oxidase (SSAO) activity is related to oxidative stress and subchronic inflammation in streptozotocin-induced diabetic rats. Neurochem Int 2006;48:746–52
   PubMed Web of Science ®Google Scholar
• Boomsma F, Pedersen-Bjergaard U, Agerholm-Larsen B, et al. Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus. Diabetologia 2005;48:1002–7
   PubMed Web of Science ®Google Scholar
• Boomsma F, Derkx FHM, van den Meiracker AH, et al. Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. Clin Sci (Lond) 1995;88:675–9
   PubMed Web of Science ®Google Scholar
• Abella A, Garcia-Vicente S, Viguerie N, et al. Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner. Diabetologia 2004;47:429–38
   PubMed Web of Science ®Google Scholar
• Salmi M, Stolen C, Jousilahti P, et al. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol 2002;161:2255–62
   PubMed Web of Science ®Google Scholar
• Stolen CM, Madanat R, Marti L, et al. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications. FASEB J 2004;18:702–4
   PubMed Web of Science ®Google Scholar
• Karim S, Liaskou E, Fear J, et al. Dysregulated hepatic expression of glucose transporters in chronic disease: contribution of semicarbazide-sensitive amine oxidase to hepatic glucose uptake. Am J Physiol Gastrointest Liver Physiol 2014;307:G1180–90
   PubMed Web of Science ®Google Scholar
• Marti L, Abella A, Carpéné C, et al. Combined treatment with benzylamine and low dosages of vanadate enhances glucose tolerance and reduces hyperglycemia in streptozotocin-induced diabetic rats. Diabetes 2001;50:2061–8
   PubMed Web of Science ®Google Scholar
• Deng Y, Yu PH. Simultaneous determination of formaldehyde and methylglyoxal in urine: involvement of semicarbazide-sensitive amine oxidase-mediated deamination in diabetic complications. J Chromatogr Sci 1999;37:317–22
   PubMed Web of Science ®Google Scholar
• Gubisne-Haberle D, Hill W, Kazachkov M, et al. Protein cross-linkage induced by formaldehyde derived from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine. J Pharmacol Exp Ther 2004;310:1125–32
   PubMed Web of Science ®Google Scholar
• Yu PH, Zuo DM. Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells: possible consequences for diabetes. Diabetes 1993;42:594–603
   PubMed Web of Science ®Google Scholar
• Nunes SF, Figueiredo IV, Pereira JS, et al. Monoamine oxidase and semicarbazide-sensitive amine oxidase kinetic analysis in mesenteric arteries of patients with type 2 diabetes. Physiol Res 2011;60:309–15
   PubMed Web of Science ®Google Scholar
• Sun P, Solé M, Unzeta M. Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia. Cerebrovasc Dis 2014;37:171–80
   PubMed Web of Science ®Google Scholar
• Hernandez-Guillamon M, Garcia-Bonilla L, Solé M, et al. Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke. Stroke 2010;41:1528–35
   PubMed Web of Science ®Google Scholar
• Ma Q, Manaenko A, Khatibi NH, et al. Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice. J Cereb Blood Flow Metab 2011;31:881–93
   PubMed Web of Science ®Google Scholar
• Garpenstrand H, Ekblom J, Bäcklund LB, et al. Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy. Diab Med 1999;16:514–21
   PubMed Web of Science ®Google Scholar
• Grönvall-Nordquist JL, Backlund LB, Garpenstrand H, et al. Follow-up of plasma semicarbazide-sensitive amine oxidase activity and retinopathy in Type 2 diabetes mellitus. J Diab Complications 2001;15:250–6
   PubMed Web of Science ®Google Scholar
• Murata M, Noda K, Fukuhara J, et al. Soluble vascular adhesion protein-1 accumulates in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2012;53:4055–62
   PubMed Web of Science ®Google Scholar
• Almulki L, Noda K, Nakao S, et al. Localization of vascular adhesion protein-1 (VAP-1) in the human eye. Exp Eye Res 2010;90:26–32
   PubMed Web of Science ®Google Scholar
• Merinen M, Irjala H, Salmi M, et al. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am J Pathol 2005;166:793–800
   PubMed Web of Science ®Google Scholar
• Noda K, Nakao S, Zandi S, et al. Vascular adhesion protein-1 regulates leukocyte transmigration rate in the retina during diabetes. Exp Eye Res 2009;89:774–81
   PubMed Web of Science ®Google Scholar
• Yoshikawa N, Noda K, Shinoda H, et al. Serum vascular adhesion protein-1 correlates with vascular endothelial growth factor in patients with type II diabetes. J Diabetes Complications 2013;27:162–6
   PubMed Web of Science ®Google Scholar
• Nakao S, Noda K, Zandi S, et al. VAP-1-mediated M2 macrophage infiltration underlies IL-1β- but not VEGF-A-induced lymph- and angiogenesis. Am J Pathol 2011;178:1913–21
   PubMed Web of Science ®Google Scholar
• Luo W, Xie F, Zhang Z, Sun D. Vascular adhesion protein 1 in the eye. J Ophthalmol 2013;2013:925267
   PubMed Web of Science ®Google Scholar
• Yoshikawa N, Noda K, Ozawa Y, et al. Blockade for vascular adhesion protein-1 suppresses pathological neovascularization in oxygen-induced retinopathy. Acta Ophthalmol 2013;91:e409–10
   PubMed Web of Science ®Google Scholar
• Noda K, Miyahara S, Nakazawa T, et al. Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveitis. FASEB J 2008;22:1094–103
   PubMed Web of Science ®Google Scholar
• Noda K, She H, Nakazawa T, et al. Vascular adhesion protein-1 blockade suppresses choroidal neovascularization. FASEB J 2008;22:2928–35
   PubMed Web of Science ®Google Scholar
• Fukuhara J, Kase S, Noda K, et al. Immunolocalization of vascular adhesion protein-1 in human conjunctival tumors. Ophthalmic Res 2012;48:33–7
   PubMed Web of Science ®Google Scholar
• Weston CJ, Adams DH. Hepatic consequences of vascular adhesion protein-1 expression. J Neural Transm 2011;118:1055–64
   PubMed Web of Science ®Google Scholar
• McNab G, Reeves JL, Salmi M, et al. Vascular adhesion protein 1 mediates binding of T cells to human hepatic endothelium. Gastroenterology 1996;110:522–8
   PubMed Web of Science ®Google Scholar
• Bonder CS, Norman MU, Swain MG, et al. Rules of recruitment for Th1 and Th2 lymphocytes in inflamed liver: a role for alpha-4 integrin and vascular adhesion protein-1. Immunity 2005;23:153–63
   PubMed Web of Science ®Google Scholar
• Lalor PF, Edwards S, McNab G, et al. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol 2002;169:983–92
   PubMed Web of Science ®Google Scholar
• Lalor PF, Sun PJ, Weston CJ, et al. Activation of vascular adhesion protein-1 on liver endothelium results in an NF-kappaB-dependent increase in lymphocyte adhesion. Hepatology 2007;45:465–74
   PubMed Web of Science ®Google Scholar
• Aspinall AI, Curbishley SM, Lalor PF, et al. CX(3)CR1 and vascular adhesion protein-1-dependent recruitment of CD16(+)monocytes across human liver sinusoidal endothelium. Hepatology 2010;51:2030–9
   PubMed Web of Science ®Google Scholar
• Oo YH, Banz V, Kavanagh D, et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol 2012;57:1044–51
   PubMed Web of Science ®Google Scholar
• Liaskou E, Karikoski M, Reynolds GM, et al. Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology 2011;53:661–72
   PubMed Web of Science ®Google Scholar
• Weston CJ, Shepherd EL, Claridge LC, et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. J Clin Invest 2015;125:501–20
   PubMed Web of Science ®Google Scholar
• Martelius T, Salaspuro V, Salmi M, et al. Blockade of vascular adhesion protein-1 inhibits lymphocyte infiltration in rat liver allograft rejection. Am J Pathol 2004;165:1993–2001
   PubMed Web of Science ®Google Scholar
• Lee WY, Salmi M, Kelly MM, et al. Therapeutic advantage of anti-VAP-1 over anti-α4 integrin antibody in concanavalin a-induced hepatitis. Hepatology 2013;58:1413–23
   PubMed Web of Science ®Google Scholar
• Koutroubakis IE, Petinaki E, Vardas E, et al. Circulating soluble vascular adhesion protein 1 in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002;14:405–8
   PubMed Web of Science ®Google Scholar
• Koc-Zorawska E, Malyszko J, Zbroch E, et al. Vascular adhesion protein-1 and renalase in regard to diabetes in hemodialysis patients. Arch Med Sci 2012;8:1048–52
   Web of Science ®Google Scholar
• Koc-Zorawska E, Malyszko J, Zbroch E, et al. VAP-1 in peritoneally dialyzed patients. Postepy Hig Med Dosw (Online) 2013;67:1340–4
   PubMedGoogle Scholar
• Nemcsik J, Szökö E, Soltész Z, et al. Alteration of serum semicarbazide-sensitive amine oxidase activity in chronic renal failure. J Neural Transm 2007;114:841–3
   PubMed Web of Science ®Google Scholar
• Koc-Zorawska E, Malyszko J, Malyszko JS, Mysliwiec M. VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients. Kidney Blood Press Res 2012;36:242–7
   PubMed Web of Science ®Google Scholar
• Koc-Zorawska E, Przybylowski P, Malyszko JS, et al. Vascular adhesion protein-1, a novel molecule, in kidney and heart allograft recipients. Transplant Proc 2013;45:2009–12
   PubMed Web of Science ®Google Scholar
• Wong MY, Saad S, Pollock C, Wong MG. Semicarbazide-sensitive amine oxidase and kidney disease. Am J Physiol Renal Physiol 2013;305:F1637–44
   PubMed Web of Science ®Google Scholar
• Bolt H. Experimental toxicology of formaldehyde. J Cancer Res Clin Oncol 1987;13:305–9
   Web of Science ®Google Scholar
• Heck H, Casanova M, Starr T. Formaldehyde toxicity-new understanding. Crit Rev Toxicol 1990;20:397–426
   PubMed Web of Science ®Google Scholar
• Yu P, Wright S, Fan E, et al. Physiological and pathological implications of semicarbazide-sensitive amine-oxidase. Biochem Biophys Acta 2003;1647:193–9
   PubMed Web of Science ®Google Scholar
• Singh B, Shinagawa K, Taube C, et al. Strain-specific differences in perivascular inflammation in lungs in two murine models of allergic airway inflammation. Clin Exp Immunol 2005;141:223–9
   PubMed Web of Science ®Google Scholar
• Yu PH, Lu LX, Fan H, et al. Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in lipopolysaccharide-induced pulmonary inflammation. Am J Pathol 2006;168:718–26
   PubMed Web of Science ®Google Scholar
• Dunkel J, Aguilar-Pimentel JA, Ollert M, et al. Endothelial amine oxidase AOC3 transiently contributes to adaptive immune responses in the airways. Eur J Immunol 2014;44:3232–9
   PubMed Web of Science ®Google Scholar
• Sallisalmi M, Tenhunen J, Yang R, et al. Vascular adhesion protein-1 and syndecan-1 in septic shock. Acta Anaesthesiol Scand 2012;56:316–22
   PubMed Web of Science ®Google Scholar
• Marttila-Ichihara F, Smith DJ, Stolen C, et al. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum 2006;54:2852–62
   PubMed Web of Science ®Google Scholar
• Jalkanen S, Salmi M. Cell surface monoamine oxidases: enzymes in search of a function. EMBO J 2001;20:3893–901
   PubMed Web of Science ®Google Scholar
• Nurminen EM, Pihlavisto M, Lázár L, et al. Novel hydrazine molecules as tools to understand the flexibility of vascular adhesion protein-1 ligand-binding site. J Med Chem 2011;54:2143–54
   PubMed Web of Science ®Google Scholar
• Fett N. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Clin Dermatol 2013;31:432–7
   PubMed Web of Science ®Google Scholar
• Yanaba K, Yoshizaki A, Muroi E, et al. Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease. Int J Rheum Dis 2013;16:442–7
   PubMed Web of Science ®Google Scholar
• Madej A, Reich A, Orda A, Szepietowski JC. Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. J Eur Acad Dermatol Venereol 2007;21:72–8
   PubMed Web of Science ®Google Scholar
• Nemati H, Khodarahmi R, Rahmani A, et al. Serum lipid profile in psoriatic patients: correlation between vascular adhesion protein 1 and lipoprotein (a). Cell Biochem Funct 2013;31:36–40
   PubMed Web of Science ®Google Scholar
• Asefi M, Vaisi-Raygani A, Khodarahmi R, et al. Methylentetrahydrofolatereductase (rs1801133) polymorphism and psoriasis: contribution to oxidative stress, lipid peroxidation and correlation with vascular adhesion protein 1, preliminary report. J Eur Acad Dermatol Venereol 2014;28:1192–8
   PubMed Web of Science ®Google Scholar
• Arvilommi AM, Salmi M, Kalimo K, Jalkanen S. Lymphocyte binding to vascular endothelium in inflamed skin revisited: a central role for vascular adhesion protein-1 (VAP-1). Eur J Immunol 1996;26:825–33
   PubMed Web of Science ®Google Scholar
• Arvilommi AM, Salmi M, Jalkanen S. Organ-selective regulation of vascular adhesion protein-1 expression in man. Eur J Immunol 1997;27:1794–800
   PubMed Web of Science ®Google Scholar
• Unzeta M, Solé M, Boada M, Hernández M. Semicarbazide-sensitive amine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer's disease. J Neural Transm 2007;114:857–62
   PubMed Web of Science ®Google Scholar
• del Mar Hernandez M, Esteban M, Szabo P, et al. Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging. Neurosci Lett 2005;384:183–7
   PubMed Web of Science ®Google Scholar
• Yu PH. Involvement of cerebrovascular semicarbazide-sensitive amine oxidase in the pathogenesis of Alzheimer's disease and vascular dementia. Med Hypotheses 2001;57:175–9
   PubMed Web of Science ®Google Scholar
• Ferrer I, Lizcano JM, Hernández M, Unzeta M. Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett 2002;321:21–4
   PubMed Web of Science ®Google Scholar
• Castillo V, Lizcano JM, Visa J, Unzeta M. Semicarbazide-sensitive amine oxidase (SSAO) from human and bovine cerebrovascular tissues: biochemical and immunohistological characterization. Neurochem Int 1998;33:415–23
   PubMed Web of Science ®Google Scholar
• Ekblom J, Grönvall JL, Garpenstrand H, et al. Is semicarbazide-sensitive amine oxidase in blood plasma partly derived from the skeleton? Neurobiology (Bp) 2000;8:129–35
   PubMedGoogle Scholar
• Valente T, Gella A, Solé M, et al. Immunohistochemical study of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 in the hippocampal vasculature: pathological synergy of Alzheimer's disease and diabetes mellitus. J Neurosci Res 2012;90:1989–96
   PubMed Web of Science ®Google Scholar
• Airas L, Mikkola J, Vainio JM, et al. Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis. J Neuroimmunol 2006;177:132–5
   PubMed Web of Science ®Google Scholar
• O'Rourke AM, Wang EY, Salter-Cid L, et al. Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis. J Neural Transm 2007;114:845–9
   PubMed Web of Science ®Google Scholar
• Ramsay RR. Inhibitor design for monoamine oxidases. Curr Pharm Des 2013;19:2529–39
   PubMed Web of Science ®Google Scholar
• Roessner V, Weber A, Becker A, et al. Decreased serum semicarbazide sensitive aminooxidase (SSAO) activity in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:906–9
   PubMed Web of Science ®Google Scholar
• Toiyama Y, Miki C, Inoue Y, et al. Circulating form of human vascular adhesion protein-1 (VAP-1): decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis. J Surg Oncol 2009;99:368–72
   PubMed Web of Science ®Google Scholar
• Yasuda H, Toiyama Y, Ohi M, et al. Serum soluble vascular adhesion protein-1 is a valuable prognostic marker in gastric cancer. J Surg Oncol 2011;103:695–9
   PubMed Web of Science ®Google Scholar
• Kemik O, Sümer A, Kemik AS, et al. Human vascular adhesion proteın-1 (VAP-1): serum levels for hepatocellular carcinoma in non-alcoholic and alcoholic fatty liver disease. World J Surg Oncol 2010;8:83
   PubMed Web of Science ®Google Scholar
• Yu TY, Li HY, Jiang YD, et al. Serum vascular adhesion protein-1 level predicts risk of incident cancers in subjects with type II diabetes. Cancer Epidemiol Biomarkers Prev 2014;23:1366–73
   PubMed Web of Science ®Google Scholar
• Li YI, Hung JS, Yu TY, et al. Serum vascular adhesion protein-1 predicts all-cause mortality and cancer-related mortality in subjects with colorectal cancer. Clin Chim Acta 2014;428:51–6
   PubMed Web of Science ®Google Scholar
• Kaplan MA, Kucukoner M, Inal A, et al. Relationship between serum soluble vascular adhesion protein-1 level and gastric cancer prognosis. Oncol Res Treat 2014;37:340–4
   Google Scholar
• Ferjančič Š, Gil-Bernabé AM, Hill SA, et al. VCAM-1 and VAP-1 recruit myeloid cells that promote pulmonary metastasis in mice. Blood 2013;121:3289–97
   PubMed Web of Science ®Google Scholar
• Li R, Li H, Luo HJ, et al. SSAO inhibitors suppress hepatocellular tumor growth in mice. Cell Immunol 2013;283:61–9
   PubMed Web of Science ®Google Scholar
• Chen J, Xi J, Tian Y, et al. Identification, prioritization, and evaluation of glycoproteins for aggressive prostate cancer using quantitative glycoproteomics and antibody-based assays on tissue specimens. Proteomics 2013;13:2268–77
   PubMed Web of Science ®Google Scholar
• Irjala H, Salmi M, Alanen K, et al. Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium. J Immunol 2001;166:6937–43
   PubMed Web of Science ®Google Scholar
• Yoong KF, McNab G, Hübscher SG, Adams DH. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 1998;160:3978–88
   PubMed Web of Science ®Google Scholar